Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Vaxart ( (VXRT) ).
Vaxart, Inc. faced a delisting from Nasdaq after failing to meet the conditions set by the Nasdaq Hearings Panel, which included obtaining shareholder approval and completing a reverse stock split by specified dates in 2025. Consequently, Vaxart’s common stock was suspended from trading on Nasdaq and is now quoted on the OTCQX Best Market under the symbol ‘VXRT’.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s stock score reflects strong revenue growth and promising vaccine developments, but is weighed down by profitability challenges, negative valuation metrics, and operational uncertainties.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Average Trading Volume: 1,878,368
Technical Sentiment Signal: Sell
Current Market Cap: $88.82M
For an in-depth examination of VXRT stock, go to TipRanks’ Overview page.